Captopril is named as an intervention in 3 current clinical trials in our Egypt and Canada registers. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is University of Calgary (1). The most-studied condition is Hormone Therapy. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Cardioprotection on Chemotherapy-Induced Cardiotoxicity
NCT06853951 · ClinicalTrials.gov ↗ · Cardiotoxicity
|
Phase 3 | Recruiting | Ain Shams University | Egypt |
|
Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans
NCT05442463 · ClinicalTrials.gov ↗ · Hormone Therapy
|
Observational | Recruiting | University of Calgary | Canada |
|
Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19
NCT04345406 · ClinicalTrials.gov ↗ · COVID
|
Phase 3 | Not yet open | Tanta University | Egypt |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Captopril. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testing, who have exhibited super-response to cardiac resynchronization therapy. DRUGLESS-CRT clinical trial.
2025-521780-12-00 · CTIS ↗ · Cardiovascular Diseases
|
Phase 3 | Ongoing | Andrea Di Marco | Spain |
| Lead sponsor | Trials |
|---|---|
| University of Calgary | 1 |
| Tanta University | 1 |
| Ain Shams University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Egypt | 2 | 1 |
| Clinical trials in Canada | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
3 current trials in our Egypt and Canada registers name Captopril as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in Egypt and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
University of Calgary (1), Tanta University (1) and Ain Shams University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Captopril works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Captopril works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Captopril (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.